An observational study in Pulmonary Fibrosis, sponsored by Fondazione Don Carlo Gnocchi Onlus. Enrolling by invitation at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Fondazione Don Carlo Gnocchi Onlus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Pulmonary Fibrosis with a site in Italy — 11 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Fibrosis · Italy.
Among the 31 studies in Pulmonary Fibrosis with a site in Italy, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2023, is one of 14 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 20th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →11 of the 31 studies in Pulmonary Fibrosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+ · Healthy volunteers
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
University of Modena and Reggio Emilia · Sites in Italy
Ages 18+
University of Modena and Reggio Emilia · Sites in Italy
Ages 18–80
University Magna Graecia · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is below the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.
Median enrollment 320 across the 17 interventional studies, 90 across the 14 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
Fondazione Don Carlo Gnocchi Onlus is the lead sponsor of 146 studies on the registry; 37 are open to participants now.
Fondazione Don Carlo Gnocchi Onlus has 1 study filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Fibrosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571291Fondazione IRCCS Policlinico San Matteo di PaviaDEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS | 2026-12-31 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
| NCT05310669University of Modena and Reggio EmiliaInspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis | 2027-07-01 |
| NCT07373288University of Modena and Reggio EmiliaHOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis | 2027-07-01 |
| NCT06815185IRCCS Azienda Ospedaliero-Universitaria di BolognaRehabilitation Counselling for Patients with Interstitial Lung Disease | 2027-07-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Pulmonary Fibrosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy, non-invasive ventilation therapy, and pharmacological treatments.
Patients with pulmonary fibrosis, at any stage, of any gender and age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
42 patients
Other: Psychological questionnaires
42
Other: Psychological questionnaires
46
Other: Psychological questionnaires
The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
Adherence to Pharmacological Treatment
Types of medications taken (Pirfenidone/Nintedanib/Other); assessed as the ratio between the received daily dose (RDD) and the prescribed daily dose (PDD); also evaluated using the Medication Adherence Report Scale (MARS-5), a 5-item questionnaire.
Time frame: from October 2023 to October 2025
Adherence to Oxygen Therapy
Use of oxygen and respective quantities (liters/minute at rest and during exertion).
Time frame: from October 2023 to October 2025
Adherence to Non invasive ventilation
Use of Non-Invasive Ventilation (nighttime/daytime or both; prescribed and actual hours of usage).
Time frame: from October 2023 to October 2025
Illness beliefs
Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness. Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness.
Time frame: from October 2023 to October 2025
Pharmacological treatment Beliefs
Assessed using the Beliefs about Medicines Questionnaire (BMQ), a tool designed to evaluate individuals' beliefs about medications. It has been validated for use in patients with chronic illnesses and has been shown to predict treatment adherence in other groups, such as individuals with asthma.
Time frame: from October 2023 to October 2025
Illness Expectations
Specific questions formulated to assess explicit illness expectations in Pulmonary Fibrosis are proposed.
Time frame: from October 2023 to October 2025
Illness Cognitions
Illness Cognition Questionnaire (ICQ), a questionnaire assessing three ways of cognitively evaluating the stressful and adverse nature of a chronic illness: helplessness, acceptance, and perceived benefits.
Time frame: from October 2023 to October 2025
Socio-demographic variables
Gender, age, smoking status, and number of cigarettes smoked per day. Additionally, factors such as family history of respiratory diseases, alcohol use (frequency), physical activity (frequency and type), level of education, marital status, onset of initial symptoms, and date of diagnosis will be considered.
Time frame: from October 2023 to October 2025
Clinical and medical data
Weight and height (for calculation of Body Mass Index, BMI); comorbidities (diabetes, hypertension, hypercholesterolemia, presence of other conditions), perceived symptoms (e.g., dyspnea, cough, chest pain, fatigue and weakness, muscle and joint pains, weight loss...). Additionally, parameters from respiratory function tests (particularly Forced Vital Capacity (FVC) and Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), arterial blood gas analysis) will be recorded. These data will be extracted from the latest available medical report and therefore from the last pulmonary visit conducted as part of routine clinical practice (please note that medical visits paid for by this project are not included).
Time frame: from October 2023 to October 2025
Plan to share: No
Ran from Oct 2023 to primary completion in Oct 2023, 0 months.
Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Don Carlo Gnocchi Onlus →